Critical Review: Adagio Medical (NASDAQ:ADGM) vs. Accuray (NASDAQ:ARAY)

Adagio Medical (NASDAQ:ADGM) and Accuray (NASDAQ:ARAY) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability and earnings.

Insider and Institutional Ownership

48.1% of Adagio Medical shares are held by institutional investors. Comparatively, 64.1% of Accuray shares are held by institutional investors. 7.8% of Adagio Medical shares are held by company insiders. Comparatively, 2.4% of Accuray shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Adagio Medical and Accuray”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagio Medical	$600,000.00	18.55	-$25.08 million	($1.48)	-0.34
Accuray	$401.95 million	0.07	-$49.19 million	($0.40)	-0.59

Adagio Medical has higher earnings, but lower revenue than Accuray. Accuray is trading at a lower price-to-earnings ratio than Adagio Medical, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Adagio Medical and Accuray’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adagio Medical	N/A	-661.85%	-73.35%
Accuray	-12.24%	-97.85%	-10.82%

Volatility and Risk

Adagio Medical has a beta of -0.09, indicating that its share price is 109% less volatile than the S&P 500. Comparatively, Accuray has a beta of 1.39, indicating that its share price is 39% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and price targets for Adagio Medical and Accuray, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagio Medical	1	1	2	0	2.25
Accuray	1	2	0	0	1.67

Adagio Medical presently has a consensus price target of $3.50, indicating a potential upside of 598.60%. Accuray has a consensus price target of $2.00, indicating a potential upside of 751.06%. Given Accuray’s higher probable upside, analysts clearly believe Accuray is more favorable than Adagio Medical.

About Adagio Medical

Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company’s product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. The company is based in Laguna Hills, California.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate. The company also provides the TomoTherapy platform, including the Radixact System, which allows for integrated radiation treatment planning, delivery, and data management, enabling clinicians to deliver ultra-precise treatments to approximately 50 patients per day; iDMS data management system, a fully integrated treatment planning and data management systems; and Accuray precision treatment planning system, a treatment planning and data management systems. In addition, it offers post-contract customer support, installation, training, and other professional services. The company primarily markets its products directly to customers, including hospitals and stand-alone treatment facilities through its sales organization, as well as to customers through sales agents and group purchasing organizations in the United States; and to customers directly and through distributors and sales agents internationally. Accuray Incorporated was incorporated in 1990 and is headquartered in Madison, Wisconsin.